从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，微电生理排 名第111位。 截至2025年一季报，共有7家机构持仓微电生理，其中基金7家，合计持股数166.93万股，持股市值0.33 亿元。 上海微创电生理医疗科技股份有限公司的主营业务是电生理介入诊疗与消融治疗领域创新医疗器械研 发、生产和销售，致力于提供具备全球竞争力的"以精准介入导航为核心的诊断及消融治疗一体化解决 方案"。公司的主要产品是Columbus三维心脏电生理标测系统、EasyFinder3D磁定位型可调弯标测导 管、EasyLoop3D一次性使用磁定位环形标测导管、EasyLoop环肺静脉标测导管、EasyLoop一次性使用 心内标测电极导管、EasyFinder一次性使用可调弯标测导管、EasyFinder一次性使用固定弯标测导管、 EasyStars一次性使用星型磁电定位标测导管、FireMagicCool3D冷盐水灌注射频消融导管、FireMagic3D 磁定位型心脏射频消融导管、FireMagicPreciSense3D一次性使用磁定位微电极射频消融导管、 FireMagicTrueForce ...

7月31日，微电生理今日收盘21.85元，下跌2.02%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到156.34倍，总市值102.83亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.89倍，行业中值37.06倍，微电生理排 名第110位。 股东方面，截至2025年3月31日，微电生理股东户数7764户，较上次减少209户，户均持股市值35.28万 元，户均持股数量2.76万股。 上海微创电生理医疗科技股份有限公司的主营业务是电生理介入诊疗与消融治疗领域创新医疗器械研 发、生产和销售，致力于提供具备全球竞争力的"以精准介入导航为核心的诊断及消融治疗一体化解决 方案"。公司的主要产品是Columbus三维心脏电生理标测系统、EasyFinder3D磁定位型可调弯标测导 管、EasyLoop3D一次性使用磁定位环形标测导管、EasyLoop环肺静脉标测导管、EasyLoop一次性使用 心内标测电极导管、EasyFinder一次性使用可调弯标测导管、EasyFinder一次性使用固定弯标测导管、 EasyStars一次性使用星型磁电定位标测导管、FireMagicCool3D冷盐 ...

Company Overview - Shanghai Microelectronic Electrophysiology Medical Technology Co., Ltd. focuses on the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment centered on precise interventional navigation [2] Product Portfolio - Key products include the Columbus 3D cardiac electrophysiology mapping system, EasyFinder 3D magnetic positioning adjustable mapping catheter, and various disposable mapping and ablation catheters [2] - The company’s cryoablation devices and balloon-type cryoablation catheters have been approved for inclusion in the "2024 Shanghai Biomedical 'New Excellent Drugs and Devices' Product Directory" [2] - The fourth-generation 3D cardiac electrophysiology mapping system is also listed in the "2024 Shanghai Innovative Product Recommendation Directory" [2] Financial Performance - For Q1 2025, the company reported revenue of 104 million yuan, a year-on-year increase of 16.77% [3] - Net profit reached 17.87 million yuan, showing a significant year-on-year growth of 328.63% [3] - The gross profit margin stood at 60.56% [3] Market Position - As of July 23, the company's stock closed at 20.69 yuan, with a rolling price-to-earnings (PE) ratio of 148.04, significantly higher than the industry average of 53.52 [1][3] - The total market capitalization is approximately 9.737 billion yuan [1] - The company ranks 110th in terms of PE ratio within the medical device industry [1] Shareholder Information - As of March 31, 2025, the number of shareholders is 7,764, a decrease of 209 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]

上海微创电生理医疗科技股份有限公司的主营业务是电生理介入诊疗与消融治疗领域创新医疗器械研 发、生产和销售，致力于提供具备全球竞争力的"以精准介入导航为核心的诊断及消融治疗一体化解决 方案"。公司的主要产品是Columbus三维心脏电生理标测系统、EasyFinder3D磁定位型可调弯标测导 管、EasyLoop3D一次性使用磁定位环形标测导管、EasyLoop环肺静脉标测导管、EasyLoop一次性使用 心内标测电极导管、EasyFinder一次性使用可调弯标测导管、EasyFinder一次性使用固定弯标测导管、 EasyStars一次性使用星型磁电定位标测导管、FireMagicCool3D冷盐水灌注射频消融导管、FireMagic3D 磁定位型心脏射频消融导管、FireMagicPreciSense3D一次性使用磁定位微电极射频消融导管、 FireMagicTrueForce一次性使用压力监测磁定位射频消融导管等。公司冷冻消融设备、球囊型冷冻消融 导管、一次性使用压力监测磁定位射频消融导管凭借卓越性能与创新技术，获批纳入《2024年度上海市 生物医药"新优药械"产品目录》；同时，冷冻消融设备、球囊型冷冻消 ...

Group 1 - The core business of the company is the development, production, and sales of innovative medical devices in the field of electrophysiological interventional diagnosis and ablation treatment [2] - The company aims to provide globally competitive integrated solutions for diagnosis and ablation treatment, centered around precise interventional navigation [2] - The company has several key products, including the Columbus 3D cardiac electrophysiology mapping system and various disposable electrophysiological catheters [2] Group 2 - As of March 31, 2025, the company had 7,764 shareholders, a decrease of 209 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company reported a revenue of 104 million yuan in Q1 2025, representing a year-on-year increase of 16.77%, and a net profit of 17.87 million yuan, up 328.63% year-on-year, with a gross margin of 60.56% [3] - The company's rolling PE ratio reached 150.26, significantly higher than the industry average of 49.40 and the industry median of 36.13, ranking 112th in the industry [1][3]